Blueprint Medicines Corporation
BPMC
Classement en actions
#2350
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Prix de l'action
$129.46
Dernière synchronisation: 2025-07-18
Capitalisation boursière
$8.36B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Blueprint Medicines Corporation (BPMC)
Catégorie
Healthcare
Bénéfices pour Blueprint Medicines Corporation (BPMC)
Bénéfices en Mar 2025 TTM : $-153.89M
Selon les derniers rapports financiers de Blueprint Medicines Corporation, les bénéfices actuels de l'entreprise sont de $-153.89M. En 2023, l'entreprise a réalisé un bénéfice de $-506.02M, une augmentation par rapport à celui de 2022 qui était de $-552.28M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Blueprint Medicines Corporation de 2013 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $-153.89M | 133.66% |
| 2024 | $-65.86M | -86.98% |
| 2023 | $-506.02M | -8.38% |
| 2022 | $-552.28M | -13.85% |
| 2021 | $-641.08M | -303.56% |
| 2020 | $314.94M | -190.58% |
| 2019 | $-347.69M | 46.93% |
| 2018 | $-236.64M | 59.76% |
| 2017 | $-148.12M | 104.32% |
| 2016 | $-72.50M | 37.38% |
| 2015 | $-52.77M | 30.99% |
| 2014 | $-40.29M | 92.64% |
| 2013 | $-20.91M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | -3,527.62% |
US
|
|
| $-3.09B | 1,905.93% |
US
|
|
| $-4.02B | 2,509.72% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,367.53% |
NL
|
